An immunotherapy drug that could save some cancer patients from the ordeal of extreme chemotherapy may also help them live longer, researchers say. In a trial, pembrolizumab kept head and neck cancers at bay for an average of two years - five times ...
from Google Alert - health https://ift.tt/33epfmI
via IFTTT
0 comments:
Post a Comment